China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...
In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.
An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...
In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.The trial evaluated fixed-duration acalabrutinib (Calquence, AstraZeneca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results